Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,438 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 21,829 · Balance 80,438 F1: Represents shares of common stock issued in lieu of board fees. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse's IRA | 24 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24 |
| Common StockSEC Table I · non-derivative | IndirectBy WaterMill Asset Management Corp.(2) | 62,416 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 62,416 F2: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued in lieu of board fees.
F2: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 21,829 | $0.74 | $16,249.51 |
DisclosureSEC source: 0001193125-26-417969 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,438 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 8,463 | $1.92 | $16,248.96 |
DisclosureSEC source: 0001193125-26-318103 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,609 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:18 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 6,274 | $2.59 | $16,249.66 |
DisclosureSEC source: 0001193125-26-201489 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,146 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 21:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 5,622 | $2.89 | $16,247.58 |
DisclosureSEC source: 0001193125-26-014116 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,872 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| November 21, 2025 Filed Nov 27, 2025 02:26 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 5,142 | $3.16 | $16,248.72 |
DisclosureSEC source: 0001193125-25-301026 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,250 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 23:11 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 6,400 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094387 · ownership.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 6,400 shares Expires 2035-07-03 F3 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of July 3, 2025, with any amount that remains unvested on the date immediately preceding the Company's 2026 annual general meeting of stockholders vesting thereon. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 23:11 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 4,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094387 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,133 F1 · balance_after: Represents a grant of restricted stock units (RSUs) which immediately vested upon grant. After the reported acquisition of the RSUs, the reporting person owned in aggregate 33,133 shares of common stock (29,083 previously owned shares, plus the instant grant of 4,034 RSUs). Read SEC document |
| June 24, 2025 Filed Jun 27, 2025 01:19 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseSeries A-2 Convertible Preferred Stock · Derivative | 600 | $4.49 Strike: $4.49 | $2,694.00 |
DisclosureSEC source: 0000950170-25-090587 · ownership.xml · derivative · entry 5 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Watermill Asset Management Corp Disclosed balance after: 600 Underlying: Common Stock · 133,630.29 shares Expires not disclosed F2 · derivative.expiration_date: The preferred stock is perpetual and therefore has no expiration date. F1 · ownership.nature: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill. Read SEC document |
| April 13, 2025 Filed Apr 16, 2025 00:42 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 20,804 | $2.92 | $60,747.68 |
DisclosureSEC source: 0000950170-25-054436 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,083 Read SEC document |
| April 13, 2025 Filed Jun 27, 2025 01:19 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 20,804 | $2.92 | $60,747.68 |
DisclosureSEC source: 0000950170-25-090587 · ownership.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,083 Read SEC document |
| April 11, 2025 Filed Apr 16, 2025 00:42 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseSeries A-1 Convertible Preferred Stock · Derivative | 500 | $2.76 Strike: $2.76 | $1,380.00 |
DisclosureSEC source: 0000950170-25-054436 · ownership.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By WaterMill Asset Management Corp. Disclosed balance after: 500 Underlying: Common Stock · 181,159 shares Expires not disclosed F2 · derivative.expiration_date: The preferred stock is perpetual and therefore has no expiration date. F3 · derivative.underlying_shares: The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance. F1 · ownership.nature: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill. Read SEC document |
| April 11, 2025 Filed Jun 27, 2025 01:19 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseSeries A-1 Convertible Preferred Stock · Derivative | 500 | $2.76 Strike: $2.76 | $1,380.00 |
DisclosureSEC source: 0000950170-25-090587 · ownership.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By WaterMill Asset Management Corp. Disclosed balance after: 500 Underlying: Common Stock · 181,159 shares Expires not disclosed F2 · derivative.expiration_date: The preferred stock is perpetual and therefore has no expiration date. F3 · derivative.underlying_shares: The reporting person disclaims beneficial ownership of these equity securities to the extent that after giving effect of the conversion of the preferred stock and the underlying common stock issuance, the reporting person would beneficially own in the aggregate in excess of 4.99% of the outstanding shares immediately after giving effect to such conversion or issuance. F1 · ownership.nature: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 12,800 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-071399 · ownership.xml · derivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2034-06-05 F1 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:27 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-014923 · doc4.xml · derivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: One-twelfth of the shares underlying the option vest in equal monthly installments measured from June 6, 2023, with the first vesting occurring on July 6, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:05 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseCommon Stock | 750,000 | $0.65 | $487,500.00 |
DisclosureSEC source: 0000899243-22-037275 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By WaterMill Asset Management Corp. Disclosed balance after: 5,000,000 F1 · shares: The shares are directly held by WaterMill Asset Management Corp. The Reporting Person serves as the principal of WaterMill Asset Management Corp. F2 · price: The shares were purchased in a registered underwritten offering on November 29, 2022. F1 · balance_after: The shares are directly held by WaterMill Asset Management Corp. The Reporting Person serves as the principal of WaterMill Asset Management Corp. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:35 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000899243-22-024005 · doc4.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-21 F3 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:35 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024005 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,870 F1 · balance_after: Includes 946,970 shares of common stock underlying units of the Issuer (the "Units"). Each Unit is comprised of one share of common stock and one warrant to acquire one share of common stock. The Reporting Person previously purchased 946,970 Units in a private placement transaction with the Issuer. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:31 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000899243-22-023987 · doc4.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-21 F3 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:31 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023987 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,870 F1 · balance_after: Includes 946,970 shares of common stock underlying units of the Issuer (the "Units"). Each Unit is comprised of one share of common stock and one warrant to acquire one share of common stock. The Reporting Person previously purchased 946,970 Units in a private placement transaction with the Issuer. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:22 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 54,492 | $1.73 | $94,271.16 |
DisclosureSEC source: 0001209191-21-054825 · doc4.xml · nonDerivative · entry 2 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,250,000 F2 · ownership.nature: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:22 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 20,508 | $1.73 | $35,478.84 |
DisclosureSEC source: 0001209191-21-054825 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201,870 F1 · balance_after: Includes 946,970 shares of common stock underlying the Units. The Reporting Person purchased 946,970 units of the Issuer (the "Units") for $2.64 per Unit in a private placement transaction with the Issuer. Each Unit consists of one share of common stock and a warrant to acquire one share of common stock. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · derivative · entry 5 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F5 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month period after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2031-03-03 F4 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,362 F1 · shares: The shares will vest on 5/19/2021. F2 · balance_after: Includes 946,970 shares of common stock underlying the Units. The Reporting Person purchased 946,970 units of the Issuer (the "Units") for $2.64 per Unit in a private placement transaction with the Issuer. Each Unit consists of one share of common stock and a warrant to acquire one share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.